PharmaCielo Valuation Multiples

Discover PharmaCielo's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like SynBiotic, Humanoid Global Holdings, HYTN Innovations, Vitura Health and more.

PharmaCielo Overview

About PharmaCielo

PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.


Founded

2017

HQ

Canada

Employees

260

Financials (FY)

Revenue: $2M
EBITDA: ($316K)

EV

$22M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

PharmaCielo Financials

PharmaCielo reported last fiscal year revenue of $2M and negative EBITDA of ($316K).

In the same fiscal year, PharmaCielo generated $520K in gross profit, ($316K) in EBITDA losses, and had net loss of ($3M).


PharmaCielo P&L

In the most recent fiscal year, PharmaCielo reported revenue of $2M and EBITDA of ($316K).

PharmaCielo is unprofitable as of last fiscal year, with gross margin of 29%, EBITDA margin of (17%), and net margin of (141%).

See analyst estimates for PharmaCielo
Last FY202320242025202620272028
Revenue$2M$2M$3M$2M
Gross Profit$520K$148K$382K$474K
Gross Margin29%7%14%23%
EBITDA($316K)($5M)($4M)($1M)
EBITDA Margin(17%)(217%)(142%)(61%)
EBIT Margin(132%)(207%)(152%)(140%)
Net Profit($3M)($8M)($8M)($4M)
Net Margin(141%)(365%)(281%)(191%)
Net Debt$13M---

Financial data powered by Morningstar, Inc.

PharmaCielo Stock Performance

PharmaCielo has current market cap of $9M, and enterprise value of $22M.


PharmaCielo's stock price is $0.04.

PharmaCielo has an EPS (earnings per share) of $-0.01.

See more trading valuation data for PharmaCielo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$22M$9M0.1%---$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

PharmaCielo Valuation Multiples

PharmaCielo trades at 11.9x EV/Revenue multiple, and (68.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for PharmaCielo

PharmaCielo Financial Valuation Multiples

As of August 14, 2026, PharmaCielo has market cap of $9M and EV of $22M.

PharmaCielo has a P/E ratio of (3.4x).

Last FY202320242025202620272028
EV/Revenue11.9x10.1x7.9x10.4x
EV/EBITDA(68.5x)(4.6x)(5.5x)(17.1x)
EV/EBIT(9.0x)(4.9x)(5.2x)(7.5x)
EV/Gross Profit41.6x146.6x56.6x45.7x
P/E(3.4x)(1.1x)(1.1x)(2.2x)
EV/FCF(6.5x)(10.9x)(14.6x)(7.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified PharmaCielo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

PharmaCielo Margins & Growth Rates

In the most recent fiscal year, PharmaCielo reported gross margin of 29%, EBITDA margin of (17%), and net margin of (141%).

See estimated margins and future growth rates for PharmaCielo

PharmaCielo Margins

Last FY202420252026202720282029
Gross Margin29%14%23%29%
EBITDA Margin(17%)(142%)(61%)(17%)
EBIT Margin(132%)(152%)(140%)(132%)
Net Margin(141%)(281%)(191%)(141%)
FCF Margin(182%)(54%)(138%)(182%)

PharmaCielo Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth28%(25%)(12%)
Gross Profit Growth159%24%10%
EBITDA Growth(16%)(68%)(75%)
EBIT Growth(6%)(31%)(17%)
Net Profit Growth(1%)(49%)(35%)
FCF Growth(25%)92%16%

Data powered by FactSet, Inc. and Morningstar, Inc.

PharmaCielo Operational KPIs

PharmaCielo's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

PharmaCielo's Rule of 40 is (30%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PharmaCielo's Rule of X is (48%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for PharmaCielo
Last FY202320242025202620272028
Rule of 40(30%)---
Bessemer Rule of X(48%)---
Revenue per Employee$0.0M---
Opex per Employee$0.0M---
S&M Expenses to Revenue0%3%(0%)0%
G&A Expenses to Revenue157%202%160%158%
Opex to Revenue160%213%166%163%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

PharmaCielo Competitors

PharmaCielo competitors include SynBiotic, Humanoid Global Holdings, HYTN Innovations, Vitura Health, Avicanna, CordovaCann, Weed, Ubiquitech Software, Peak Processing and Strainsforpains.

Most PharmaCielo public comparables operate across Cannabis, CannaTech and ViceTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
SynBiotic0.7x-(5.1x)-
Humanoid Global Holdings753.4x-(4.8x)-
HYTN Innovations8.9x-(13.0x)-
Vitura Health0.2x-3.2x-
Avicanna0.6x-(8.2x)-
CordovaCann0.8x-(13.1x)-
Weed--(3.4x)-
Ubiquitech Software----

This data is available for Pro users. Sign up to see all PharmaCielo competitors and their valuation data.

Start Free Trial

PharmaCielo VC Funding History

Before going public, PharmaCielo raised $13M in total equity funding, across 3 rounds.


PharmaCielo Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Dec-17Seed-$2M--
Jul-17Series A-$7M--
May-16Seed-$4M--

Acquisitions by PharmaCielo

PharmaCielo has acquired 2 companies to date.

Last acquisition by PharmaCielo was on July 12th 2019. PharmaCielo acquired Melodiol Global Health for $79M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by PharmaCielo

Melodiol Global Health
Ubiquo Telemedicine
Description
-
-
HQ CountryAustraliaColombia
HQ City
-
-
Deal Date12 Jul 201920 Apr 2018
Valuation$79M$1M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all PharmaCielo acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About PharmaCielo

When was PharmaCielo founded?PharmaCielo was founded in 2017.
Where is PharmaCielo headquartered?PharmaCielo is headquartered in Canada.
How many employees does PharmaCielo have?As of today, PharmaCielo has over 260 employees.
Is PharmaCielo publicly listed?Yes, PharmaCielo is a public company listed on OTCM.
What is the stock symbol of PharmaCielo?PharmaCielo trades under PCLOF ticker.
When did PharmaCielo go public?PharmaCielo went public in 2018.
Who are competitors of PharmaCielo?PharmaCielo main competitors include SynBiotic, Humanoid Global Holdings, HYTN Innovations, Vitura Health, Avicanna, CordovaCann, Weed, Ubiquitech Software, Peak Processing, Strainsforpains.
What is the current market cap of PharmaCielo?PharmaCielo's current market cap is $9M.
What is the current revenue of PharmaCielo?PharmaCielo's last fiscal year revenue is $2M.
What is the current EV/Revenue multiple of PharmaCielo?Current revenue multiple of PharmaCielo is 11.9x.
Is PharmaCielo profitable?No, PharmaCielo is not profitable.
How many companies PharmaCielo has acquired to date?As of August 2026, PharmaCielo has acquired 2 companies.
What was the largest acquisition by PharmaCielo?$79M acquisition of Melodiol Global Health on 12th July 2019 was the largest M&A PharmaCielo has done to date.
What companies PharmaCielo acquired?PharmaCielo acquired Melodiol Global Health and Ubiquo Telemedicine.
In how many companies PharmaCielo has invested to date?PharmaCielo hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to PharmaCielo

Lists including PharmaCielo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial